Skip Navigation

Bacteriophage Therapy:
An Alternative Strategy to Combat Drug Resistance
July 20 – 21, 2015
NIAID Conference Facility
5601 Fishers Lane, Rockville MD


MDR Kleb.jpg
Human neutrophil interacting with MDR Klebsiella pneumoniae (in pink)


Antimicrobial resistance (AMR) represents a serious public health threat and is a research priority for NIH. Last year NIAID put forward its strategic vision to reduce AMR (1), and included phage therapy as one potential approach that could be applied.  In Feb 2015, the National Action Plan for Combatting Antibiotic-Resistant Bacteria was published (2) and phage and phage products were highlighted, among several non-traditional therapeutic strategies, as a means to specifically target AMR pathogens while preserving the natural microbiota.  The workshop described below was organized to assess the current status and clinical use of bacteriophage-related products as part of a comprehensive game plan to combat AMR.
WORKSHOP OBJECTIVES:  This workshop will bring together members of the medical, academic and commercial sectors, along with representatives of regulatory agencies, to discuss the potential of bacteriophages and related products for therapy and prevention of infectious disease.  The goals of the workshop are to provide background on the historical and current uses of phages in medicine and to identify key challenges and opportunities for development of phage-related products, particularly as relates to strategies to mitigate antibacterial drug resistance.


For assistance, please contact:  François Franceschi or Randall Kincaid.

Last Updated May 21, 2015

Last Reviewed May 21, 2015